TG Therapeutics Inc. has announced the upcoming presentation of new clinical data on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, scheduled for February 5-7, 2026, in San Diego, California. The presentations will include real-world infusion experiences from the ENABLE Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab, as well as the study design of a Phase 3, randomized, double-blind trial comparing ublituximab to fingolimod in children and adolescents with relapsing multiple sclerosis (ULTIMATE KIDS II). These results will be presented during Poster Session 1 on February 5, 2026, and additional data will be made available on the company’s website following the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642909) on January 27, 2026, and is solely responsible for the information contained therein.